The methyl-CpG-binding protein MeCP2 was discovered over 15 years ago as part of a search for proteins that selectively bind methylated DNA. It is a nuclear protein that is largely chromatinbound and has a strong preference for binding to methylated DNA sequences in vivo. Evidence from model systems shows that MeCP2 can recruit the Sin3a co-repressor complex to promoters leading to transcriptional repression, therefore suggesting that MeCP2 can interpret the DNA methylation signal to bring about gene silencing. Mutations in the human MECP2 gene cause the autism spectrum disorder Rett Syndrome. MeCP2 is most highly expressed in neurons, and mice lacking this protein show symptoms that strikingly parallel those of Rett patients. Surprisingly, these symptoms are efficiently reversed by delayed activation of a 'stopped' Mecp2 gene, raising hopes that human Rett syndrome may also be reversible. Future studies of MeCP2 promise to shed light upon brain function, neurological disease and the biology of DNA methylation.
Introduction [1] . Two sorts of epigenetic system have traditionally been studied: DNA methylation [2] and the polycomb/trithorax system [3] . Other epigenetic categories include transcriptional silencing triggered by double-stranded RNA interference [4, 5] , and silencing or activity that responds to localization of genes within the nucleus [6, 7] . All of these processes appear to be closely interwoven with histone modification, which is itself a diverse and complex system of chromosome marking [8] . The present article focuses on DNA methylation, bearing in mind its relationship to other epigenetic processes. DNA methylation occurs at approx. 70% of cytosine residues in the genomes of humans and other mammals, almost always in the sequence 5 -CpG-3 . We know two generic consequences of its presence, and both have important implications for human health. First, CpG sites are hotspots for mutation, as 5-methylcytosine (m 5 C) frequently mutates to T [9] [10] [11] . Mutability of m 5 C is arguably the most important single cause of human genetic disorders and cancer. Secondly, CpG methylation at gene promoters can lead to stable transcriptional shutdown; aberrant gene silencing by methylation of CpG-dense promoters is a feature of fragile X syndrome and many cancers [12, 13] .
To understand the biological significance of DNA methylation, or indeed of any epigenetic system, there are two key questions that need to be answered: (i) what creates patterns of DNA/chromatin marking?, and (ii) how are the patterns read by the cell to generate biological outcomes? The present article describes our attempts to answer the second of these questions in relation to DNA methylation. There are potentially three ways in which DNA methylation can cause gene silencing: (i) by directly altering the higher-order structure of chromatin so as to change DNA accessibility; (ii) by interfering with the productive interaction between a particular DNA-binding protein (e.g. a transcriptional activator) and its cognate binding site on genomic DNA; (iii) by attracting proteins that have an affinity for methylated DNA, which then mediate downstream biological effects. We have studied the third of these categories, although it is evident that the second [14, 15] and, to a small extent, third possibilities [16] are both of biological significance. MBD1 and Kaiso. Each MBP is associated with a different co-repressor, although there is evidence for alternative protein partners for some of these proteins. CAF1, chromatin assembly factor 1; HDACs, histone deacetylases; HP1, heterochromatin protein 1; N-CoR, nuclear receptor co-repressor; SETDB1, SET domain, bifurcated 1.
Methyl-CpG-binding proteins
Some years ago, work in my laboratory detected a DNAbinding activity that is specific for methylated CpG in extracts from mammalian cells [17] and speculated that this activity functioned to interpret the DNA methylation signal. Following purification of the first such protein, MeCP2 [18] , bioinformatic analysis detected relatives that share a related DNA-binding domain and also bind specifically to methylated sites in vivo and in vitro [19, 20] . This domain is known as the MBD (methyl-CpG-binding domain).
More recently an unrelated protein domain found in Kaiso and its relatives was also found to bind preferentially to methyl-CpG [21, 22] and shown to participate in DNA methylation-dependent gene silencing [23] . Collectively, we refer to proteins that bind specifically to methylated DNA in vivo and in vitro as 'MBPs' (methylated DNA-binding proteins). We and others have established that four MBPs, MeCP2 [24] , MBD1 [25, 26] , MBD2 [27, 28] and Kaiso [21, 23] , can act as transcriptional repressors in vivo (Figure 1 ). Our finding, coincident with work in Alan Wolffe's laboratory, that MeCP2 recruits histone deacetylases, established the first mechanistic link between methylated DNA and chromatin [29, 30] . Subsequently, each MBP has been implicated in recruiting a different co-repressor complex to methylated sites ( Figure 1 ) [23, 27, 31, 32] . There is evidence that the co-repressors then modify local chromatin structure in order to enforce transcriptional silencing [33] .
To determine the physiological consequences of MBP deficiency, we created gene knockouts in mice. We disrupted the genes for Mecp2 [34] , Mbd2 [35] , Mbd3 [35] , Mbd4 [36] and Kaiso [37] and have studied the resulting phenotypes. Knockout of the Mbd1 gene was reported by others [38] . Several of our mouse lines have turned out to be relevant to Xenopus oocyte extract and incubated with radioactively labelled MeCP2. The large plasmid was methylated at CpGs (filled circle lollipops above plot), while the other plasmid was left unmethylated (A) and vice versa (B). Plasmid mini-chromosomes were resolved by sucrose gradient centrifugation ( ). MeCP2 (᭹) only associated with the methylated plasmid. Based on data taken from [24] .
human disease. The human MECP2 gene is mutated in the neurological disorder Rett syndrome [39] , and the Mecp2-null mouse is a convincing model of this condition [34] (see below). Mbd4 loss specifically increases CpG mutation rates and promotes intestinal cancer on a tumour-susceptible background [36] . Loss of Mbd2, on the other hand, protects mice against intestinal cancer on the same susceptible background [40] . Mbd2-deficiency also leads to defects in gene silencing. For example, shutdown of the Xist gene on the active X chromosome is leaky in cells from Mbd2-null mice [41] . In differentiated T-helper cells, expression of the genes for interleukin 4 and interferon γ is also incompletely silenced [42] and, in the colon, genes that are normally expressed only in the pancreas and duodenum are derepressed [43] .
MeCP2 and Rett syndrome
The present review deals with the MBP MeCP2, which was identified through its specific affinity for DNA sequences that contain the methylated dinucleotide sequence 5 -CpG-3 [18] . Subsequent studies involving both immunofluorescent localization and chromatin immunoprecipitation established that MeCP2 is a nuclear protein whose binding to chromosomes is dependent on DNA methylation in vivo [44] [45] [46] . Moreover, assembly of MeCP2 on to nucleosomes in a Xenopus oocyte extract shows high specificity for methylated DNA (Figure 2 ) [24] . Regarding the function of MeCP2, DNA methylation at CpG is known to repress transcription, and MeCP2 can mediate this effect by recruiting the mSin3a co-repressor to methylated sites in the genome [29, 30] . The mSin3a complex contains histone deacetylases that alter the modification state of chromatin and contribute to transcriptional repression. Interactions with other proteins besides mSin3a have also been reported, although their biological significance remains unclear (listed in [47] ). In addition to its DNA-binding specificity, there have been reports that MeCP2 is an RNA-binding protein that can affect the pattern of alternative splicing in the brain [48] . Also, nucleosomal compaction in vitro independent of DNA methylation has been reported [49] .
MeCP2 acquired biomedical importance with the discovery that a profound autism spectrum disorder, Rett syndrome, is almost exclusively caused by mutations in the human MECP2 gene [39] . The MECP2 gene is X-linked, and Rett syndrome affects females who are heterozygous for a new mutation [50] . Symptoms appear 6-18 months after birth when the child enters a 'crisis', usually accompanied by a marked deceleration of head growth. Transient social withdrawal occurs, together with severely impaired expressive and receptive language, severe psychomotor retardation and stereotyped hand movements. Also characteristic are gait and truncal dyspraxia, breathing abnormalities, susceptibility to seizures and scoliosis. Despite these symptoms, patients often survive beyond their third decade of life, but are dependent on intensive support. Males with equivalent mutations exhibit neonatal encephalopathy and rarely survive for more than 2 years. MECP2 mutations are also causally implicated in other neurological conditions, including learning disability, autism and X-linked mental retardation [51] . Moreover, duplication of the MECP2 gene locus has been found to cause developmental delay and other clinical symptoms in males, suggesting that overexpression of the gene is also deleterious [52] .
MeCP2 binding to DNA
Rett syndrome does not run in families, as neither females nor males with a mutation can reproduce, except in rare circumstances. Almost all of the mutations that cause Rett syndrome arise newly in the germ cells of a parent. As with other genetic disorders, the kinds of mutations causing the disease include frameshift, deletion, nonsense and missense mutations. Frameshift and nonsense mutations invariably truncate the protein and therefore eliminate regions C-terminal to the mutated site. Missense mutations are therefore a better guide to important regions of the protein, as only one amino acid is affected. Interestingly, more than half of the missense mutations that cause Rett syndrome are clustered within the DNA-binding domain that was identified by deletion analysis ( Figure 3 ) [53] . Previous studies have tested the effects of Rett syndrome mutations on DNA binding and established that the majority of those within the MBD reduce the affinity for methylated DNA [54] [55] [56] .
Solution structures of unliganded MBDs of MBD1 [57] and MeCP2 [58] and of a DNA-bound MBD of MBD1 [59] have been established by NMR. On the basis of the structure of the MBD1-DNA complex, it was inferred that the specificity for methylated DNA was due to contacts between a hydrophobic patch on the MBD that interacts with the DNA methyl groups directly. The X-ray structure of the MeCP2 MBD complex [60] contradicts this conclusion, however, as binding to methylated DNA was found to be intimately dependent on hydration. To obtain a high-resolution crystal structure of the MeCP2 MBD-DNA complex, we took advantage of evidence that a run of four or more AT bases adjacent to the symmetrical methyl-CpG dinucleotides promotes highaffinity binding of MeCP2 [61] . A polypeptide corresponding to amino acids 77-167 of the MeCP2 MBD was expressed and co-crystallized with a 20 bp DNA fragment of promoter III of the mouse BDNF (brain-derived neurotrophic factor) gene. This sequence contains a central methyl-CpG pair and an AT run, and is implicated as an MeCP2 target [62, 63] .
Although the structure grossly resembled the solution structure of the MBD1 MBD complexed with DNA, the methyl-CpG-binding surface turned out to be unexpectedly hydrophilic. Of 25 interactions between the methyl groups and neighbouring atoms, only two were classically hydrophobic in character. Strikingly, MeCP2 recognition of methyl-CpG involved five structured water molecules in the DNA major groove. Similar C-H . . . O hydrogen bonds have been implicated in methyl group recognition during lysine methylation by SET (suppressor of variegation/enhancer of zeste/trithorax) domain lysine methyltransferases [64] . Analysis of X-ray structures of DNA containing m 5 C established that the great majority detected water molecules associated with the cytosine methyl groups via C-H . . . O hydrogen bonds. The data suggest that structurally conserved water molecules that are present in the major groove due to cytosine methylation determine the methyl-CpG-binding specificity of MeCP2 and other MBPs.
MeCP2 partners
The function of a protein can be deduced by identification of its interacting partners. For example, the association of MeCP2 with the co-repressor molecule mSin3a established a link between DNA methylation and deacetylation of chromatin [29, 30] . Subsequently, MeCP2 has been reported to interact with several other protein partners, including histone H3 lysine 9 methyltransferase activity [65] , c-Ski [66] , DNMT1 (DNA methyltransferase 1) [67] , Co-Rest [68] , LANA (latency-associated nuclear antigen) [69] , PU.1 [70] , splicing factors [71] , Y-box-binding protein 1 [48] , Brm [72] and RNA [73] . The relative importance of these interactions, particularly their contributions to the function of MeCP2 in neurons, remains to be clarified. Recently, we identified an interacting protein that, like MeCP2 itself, is mutated in X-linked mental retardation [47] . ATRX (α-thalassaemia/mental retardation, X-linked) is a SWI2/SNF2 DNA helicase/ATPase that is mutated in X-linked mental retardation with α-thalassaemia syndrome [74, 75] . MeCP2 can recruit the helicase domain of ATRX to heterochromatic foci in living mouse cells in a DNA methylation-dependent manner. Also, ATRX localization is disrupted in neurons of Mecp2-null mice.
Certain relatively mild mutations in MECP2 cause Xlinked mental retardation in males and also interfere with the MeCP2-ATRX interaction. In particular, the A140V mutant protein localizes efficiently to heterochromatic foci, but is unable to recruit the C-terminus of ATRX to these sites [47] . The A140V mutation lies within the highly conserved MBD, but has no effect on DNA binding. Binding to ATRX is, however, abolished by the A140V mutation, which therefore uncouples the DNA-binding and ATRX-binding functions of MeCP2. Thus the only measurable alteration caused by the A140V mutation is to prevent interaction with ATRX. An intriguing, but speculative, possibility is that inappropriate targeting of ATRX contributes to the neurological phenotype of Rett syndrome patients and Mecp2-null mice.
MeCP2 and gene expression
Given the role of MeCP2 as a transcriptional repressor, an obvious hypothesis to explain the disease is that genes in the brain that should be silenced by MeCP2 escape repression in its absence, leading to aberrant neuronal function. An initial attempt to test this hypothesis using microarrays detected slight alterations in gene expression that only became significant when groups of genes were considered together [76] . A candidate approach, however, successfully identified the first mammalian MeCP2 target gene, encoding BDNF [62, 63] . BDNF is one of several proteins synthesized in response to neuronal activity and is thought to be essential for converting transient stimuli into long-term changes in brain activity. Its misregulation may therefore be implicated in the pathology of Rett syndrome. Subsequent experiments have supported its involvement, as site-specific phosphorylation was shown to alter activity-dependent BDNF expression [77] . Surprisingly, BDNF levels are reduced, rather than enhanced, in Mecp2-null mice for reasons that are not understood. Mice that express extra BDNF to compensate for this deficiency display somewhat less severe symptoms, again suggesting that aspects of the phenotype may be due to misregulation of BDNF [78] .
We independently sought misexpression of brain genes in Mecp2-null mice using microarrays and differential display analysis. Both methods revealed potential target genes that are overexpressed in the absence of MeCP2. The gene for a nuclear-encoded component of the mitochondrial electrontransport chain, Uqcrc1 (ubiquinol cytochrome c reductase core protein 1), is up-regulated in the Mecp2-null brain [79] . Isolated brain mitochondria from mice that had neurological symptoms displayed abnormal oxidative respiration, as respiratory complex III of the mitochondrial electron transport chain, which contains Uqcrc1, is more active in the Mecp2-null brain than in the wild-type brain. Uqcrc1 is not overexpressed in mice that have yet to develop neurological symptoms, and brain mitochondrial respiration is also normal in these pre-symptomatic mice. The delayed onset of Uqcrc1 overexpression may mean that the effect is a secondary consequence of MeCP2 deficiency. MeCP2 is bound to the Uqcrc1 promoter, however, raising the possibility that it exerts a regulatory role in mature neurons.
Microarray experiments also revealed a group of glucocorticoid-response genes that are up-regulated in the brains of Mecp2-null mice [80] . In particular, SGK1 (serum-and glucocorticoid-inducible kinase 1) and FKBP5 (FK506-binding protein 5), a proline isomerase that associates with the glucocorticoid receptor, are both overexpressed in the absence of MeCP2 (Figure 4 ). Unlike Uqcrc1 misregulation, which is late-onset, these glucocorticoid-signalling genes are overexpressed in both pre-and post-symptomatic mice. Moreover, MeCP2 is associated with their promoters in brain. Both SGK1 and FKBP5 are up-regulated in response to the stress-response pathway that leads to transient glucocorticoid signalling. Our hypothesis is that these genes are normally repressed by MeCP2, but this repression is overcome by the glucocorticoid signalling pathway leading to their up-regulation. According to this model, without MeCP2, some aspects of glucocorticoid signalling are permanently active, even in the absence of hormone stimulation. Studies of an Mecp2-hypomorphic mutation have detected elevated corticosterone levels [81] , suggesting an alternative explanation for overexpression of glucocorticoid-regulated genes, although monitoring of this hormone in Mecp2-null mice failed to detect significantly increased levels [80] . There is ample evidence that long-term activation of the glucocorticoid signalling cascade severely affects the brain. Children treated postnatally with glucocorticoids show significantly reduced height and head circumference, poor motor skills and motor co-ordination, and significantly lower IQ scores [82] [83] [84] . Prolonged glucocorticoid exposure can cause microcephaly and reduced dendritic arborization, which are also features of Rett syndrome. It is therefore possible that misexpression of these genes plays a role in the disorder.
Studies from several laboratories have identified a variety of additional genes whose expression is altered in the absence of MeCP2 (see [85] for a review). The magnitude of the effects is small in all cases reported so far (< 3-fold). It is conceivable that misregulation of one or more of the putative MeCP2-target genes might be key contributors to the phenotype. For each of these genes, a hypothetical case can be made that misregulation would have neurological consequences that could give rise to disease. In fact overexpression of BDNF, which is reduced in Mecp2-null brains, does ameliorate somewhat the Rett syndrome-like phenotype, suggesting a role downstream of MeCP2 [78] . There is currently no experimental evidence that strongly supports involvement of the other candidates. An alternative scenario is that Rett syndrome is due to an aggregate of many slight defects in gene expression, of which only a few are currently known. These two broad scenarios have therapeutic implications. If a small number of molecular pathways were to be involved, pharmacological intervention might be targeted to the affected processes. On the other hand, a complex set of downstream effects resulting from MeCP2-deficiency may prove more difficult to address pharmacologically and this could favour a strategy of reintroducing (or reactivating) a functional MECP2 gene. To resolve these issues, it will be important to connect gene expression changes in mouse and human with aspects of the phenotype in each system.
Rett syndrome-like symptoms in mice are reversible
The delayed onset with repetitive movements and loss of speech have led to Rett syndrome being classified as an autism spectrum disorder, although there are features, such as preservation of social awareness, that differ from classical autism. An advantage to studying Rett syndrome compared with autism is its known monogenic origin. Experimental accessibility depends upon the mouse models, which we and others created initially [34, 86] . Deletion of the mouse Mecp2 gene recapitulates a number of features of Rett syndrome. Mecp2-null males appear normal for about 6 weeks, but then show reduced mobility, tremor, breathing irregularity, hindlimb clasping and abnormal gait. Symptom severity increases with age leading to death at ∼10 weeks. Female heterozygotes, which are a much closer genetic model for Rett syndrome, become symptomatic at 4-12 months of age, after a period of apparent normality during which they can produce multiple litters. Symptoms include reduced mobility, breathing irregularity, hindlimb clasping, abnormal gait, tremor and obesity (the latter is not a consistent feature of Rett syndrome). As in human females with Rett syndrome, these symptoms stabilize, permitting an apparently normal lifespan. Many of these phenotypic characteristics point to a neuronal defect, and this has been confirmed by conditional deletion of Mecp2 only in the brain, which leads to an indistinguishable phenotype [34, 86, 87] . Importantly, expression of Mecp2 in neurons alone can give rise to phenotypically normal mice, thereby proving that the mutant phenotype is largely due to absence of MeCP2 in neurons [87] .
Neurobiological studies of Mecp2-null mice have provided insight into the consequences of MeCP2 deficiency. Null males initially show apparently normal neurogenesis, followed by defects in maturation and in maintenance of neuronal structure [88] . Newly generated hippocampal neurons exhibit pronounced deficits in neuronal maturation, including altered expression of presynaptic proteins and reduced dendritic spine density [38] . Rett syndrome patient brains also show reduced dendritic arborization in some regions [89] . Electrophysiological measurements in the mutant mice show age-dependent defects in hippocampal long-term potentiation [90] . Also, long-term depression induced by repetitive low-frequency stimulation is reportedly absent in behaviourally symptomatic Mecp2-null mice, and the balance between cortical excitation and inhibition is shifted in favour of inhibition [91] .
Rett syndrome patients show abnormal neuronal morphology, but not neuronal death [89] . The possibility exists therefore that restoration of MeCP2 protein to the deficient neurons would restore full functionality. An alternative view is that neuronal development in the absence of MeCP2 causes irreversible damage that cannot subsequently be remedied. We performed an experiment to test whether the phenotypes observed in Mecp2-null and Mecp2 +/− heterozygote mice could be reversed by restoring expression of the Mecp2 gene [92] . To achieve this, we first generated a mouse line with Mecp2-lox-stop allele that is unable to produce the MeCP2 protein.
The Stop cassette could be efficiently deleted at will when combined with a transgene expressing the Cre recombinase under tamoxifen control. Activation of the Mecp2 gene in lox-stop male mice with advanced (near-terminal) symptoms caused dramatic reversal of most overt aspects of the phenotype and prevented death. Reversal of most or all symptoms was also seen in mature female mice with Rett syndrome-like symptoms ( Figure 5 ). The results suggest that, in mice at least, the profound defects caused by lack of MeCP2 are reversed if MeCP2 is subsequently made available. This unexpected result has implications for therapeutic approaches to Rett syndrome and perhaps other autism spectrum disorders.
MeCP2 and the maintenance of neuronal function
What do these findings tell us about the nature of Rett syndrome? It is not a neurodegenerative disorder, as neuronal death, which is characteristic of Huntington's, Alzheimer's and Parkinson's diseases, is not seen. As a result, Rett syndrome is widely categorized as a 'neurodevelopmental' disorder, implying that the symptoms are due to failures in neuronal development. Our results show that neurons can develop in the complete absence of MeCP2 and acquire defects in structure and function, yet can recover almost completely if the protein is restored at a late stage. This suggests that there is no lasting defect due to development in the absence of MeCP2 that cannot be repaired simply by putting the protein back.
To explain the reversibility of the Rett syndrome-like symptoms in mice, we propose that MeCP2 is primarily involved in maintaining the function in mature neurons ( Figure 6 ). Most neurons are born pre-natally and undergo complex morphological and biochemical changes during synaptogenesis. The resulting cells must maintain their identity for years. Assuming that neuronal identity is determined to a great extent by patterns of gene activity, it follows that mature neurons must stabilize the specific gene expression profiles that define their roles in the nervous system. On the basis of its ability to function as a transcriptional repressor, we suggest that MeCP2 stabilizes gene expression patterns by interpreting the DNA methylation signal to silence genes locally. We propose that the function of MeCP2 is dictated by its localization on chromosomes, which is in turn determined by patterns of genomic DNA methylation. According to this view, DNA methylation patterns arise during neuronal development in a manner that is independent of the presence or absence of MeCP2. Thus neurons that have developed in an Mecp2-null mouse will possess DNA methylation patterns that are indistinguishable from those in wild-type neurons. MeCP2 that has been provided to neurons after their development is complete can therefore occupy cognate chromosomal sites as dictated by the DNA methylation pattern in that particular neuron. As a result, neurons whose gene expression pattern has degenerated with time due to imperfect maintenance will regain their appropriate gene expression profile, and take on normal functions. Future research will attempt to test this model. In its absence, gene silencing becomes leaky (grey arrow, left-hand panel) and neuronal identity is compromised. According to the model, MeCP2 is targeted to genomic sites by DNA methylation (black lollipops) alone. MeCP2 plays no role in establishing DNA methylation patterns which therefore form normally in its absence. When MeCP2 is restored (grey triangle, right-hand panel), it resumes normal genomic distribution, as dictated by the DNA methylation pattern. Its function is to stabilize silencing of genes with methylated regulatory sequences.
Concluding remarks
MeCP2 was discovered through 'blue-skies' research into possible mediators of the DNA methylation signal. Once the MECP2 gene was found to be mutated in Rett syndrome, the early work provided a basis for understanding its potential role in cells. Even with this advantage, linking the phenotypes of human and animal models with the biochemical properties of the protein has not been straightforward. Numerous uncertainties remain, often reflecting our ignorance of neuron biology. The potential benefits of studying MeCP2 are therefore great. By researching its biology in detail, we have the opportunity not only to understand the role of epigenetic phenomena in development, but also to illuminate basic neuroscience. There are also compelling clinical reasons for studying MeCP2. Rett syndrome is an autism spectrum disorder with a single known genetic origin, so we also have the chance to seek therapeutic opportunities for treatment of this and perhaps related disorders. 
